|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
V10BX03
|
|
gptkbp:CASNumber
|
888504-28-7
|
|
gptkbp:chemicalFormula
|
gptkb:RaCl2
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:genericName
|
gptkb:radium_Ra_223_dichloride
|
|
gptkbp:halfLife
|
11.4 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xofigo
|
|
gptkbp:indication
|
symptomatic bone metastases without known visceral metastatic disease
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bayer
|
|
gptkbp:mechanismOfAction
|
alpha particle-emitting radiopharmaceutical
|
|
gptkbp:notRecommendedFor
|
visceral metastases
|
|
gptkbp:pregnancyCategory
|
not for use in pregnancy
|
|
gptkbp:radioisotope
|
gptkb:radium-223
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
neutropenia
thrombocytopenia
peripheral edema
|
|
gptkbp:target
|
bone metastases
|
|
gptkbp:UNII
|
8Y6I1W0A1T
|
|
gptkbp:usedFor
|
treatment of castration-resistant prostate cancer with bone metastases
|
|
gptkbp:bfsParent
|
gptkb:Advanced_Accelerator_Applications
gptkb:radium-223
|
|
gptkbp:bfsLayer
|
6
|